Pharmaceutical Analysis of One Case of Exfoliative Dermatitis Induced by Moxifloxacin and Metronidazol

Chinese Journal of Pharmacovigilance ›› 2011, Vol. 8 ›› Issue (7): 447-448.

Previous Articles

Pharmaceutical Analysis of One Case of Exfoliative Dermatitis Induced by Moxifloxacin and Metronidazol

LUO Min, TANG Yao^*

Dept.of Pharmacy, West China Hospital of Sichuan University, Chengdu 610041, China,Sichuan Chengdu 610041, China

Received:2010-09-03 Online:2011-07-10 Published:2015-07-13

Abstract

Abstract: By reporting one case of exfoliative dermatitis which was induced by Moxifloxacin Hydrochloride and Sodium Chloride Injection and Metronidazole Injection, summed up their status, adverse reactions and pharmaceutical care points, in order to attract the attention of clinicians and pharmacists and to promote the rational medication.

Key words: moxifloxacin, metronidazole, exfoliative dermatitis, adverse eeactions, pharmaceutical care

CLC Number:

LUO Min, TANG Yao. Pharmaceutical Analysis of One Case of Exfoliative Dermatitis Induced by Moxifloxacin and Metronidazol[J]. Chinese Journal of Pharmacovigilance, 2011, 8(7): 447-448.

[1]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[2]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[3]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[4]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[5]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[6]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[7]	YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling. Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
[8]	YAO Xin, GE Qiuge, LI Yamin, WANG Yifan, LI Yuanyuan, LIU Zhiqiang. Adverse drug reactions caused by new anti-tumor drugs from 2018 to 2022 in one hospital [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1273-1278.
[9]	ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.
[10]	SU Su, WU Shiqi, ZHANG Qingxia, YAN Suying. Pharmaceutical care of a patient with indapamide-induced agranulocytosis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1282-1285.
[11]	WANG Yanting, ZHANG Yuanyuan, CHEN Yiran, SUN Jie, ZHU Yu, YANG Liyan, WU Zhigui, SHEN Lijun, CHENG Min, LI Guohui. Balanced decision between anti-infective and antitumor therapies and pharmaceutical care for a malignant tumor patient [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1168-1172.
[12]	WANG Qiru, ZUO Li, DU Qiong, YE Ling, RUAN Cong, ZHAI Qing, XU Rui. Pharmaceutical care of a patient with grade Ⅳ myelosuppression induced by olapalil [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.
[13]	SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.
[14]	TANG Jingya. Pharmaceutical care by a clinical pharmacists in the treatment of parenteral nutrition related hepatic damage: a case report [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 786-788.
[15]	LI Yanming, ZHAO Zhigang. Evidence-based ibrutinib-related adverse reactions and pharmaceutical care [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 807-811.

Pharmaceutical Analysis of One Case of Exfoliative Dermatitis Induced by Moxifloxacin and Metronidazol

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics